Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia

Immune Thrombocytopenia Clinical Trial

Official title:

Extension Study of Herombopag in Children and Adolescents With Chronic Primary Immune Thrombocytopenia

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05685420
• Other study ID #: HR-TPO-ITP-III-PED-EXT
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: January 23, 2023
• Est. completion date: June 30, 2024

Study information

• Verified date: January 2023
• Source: Jiangsu HengRui Medicine Co., Ltd.
• Contact: Zhenyi Zhu, M.M
• Phone: +0518-82342973
• Email: zhenyi.zhu[@]hengrui.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this extended study is to enable subjects who are currently receiving the PartB experimental drug in the HR-TPO-ITP-III-PED clinical trial .To continue receiving the experimental drug after the completion of the clinical trial if they benefit from the treatment at the end of the clinical trial.Until the study physician determines that the subject has failed treatment or that the subject can no longer benefit from treatment or extends the study treatment for 6 months.In addition, the secondary purpose of this extended study was to observe the long-term efficacy and safety of tripodal in children and adolescents.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 117
• Est. completion date: June 30, 2024
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 17 Years

Eligibility

Inclusion Criteria:

1. Subjects who have completed PartB of HR-TPO-ITP-III-PED clinical trial and have achieved platelet response.

2. Subjects who have signed the informed consent for the extended study.

3. Subjects with potential fertility(e.g. women who have menarche or men who have sperm loss) should agree to use effective contraception during their participation in the extended study and within 28 days after their last dose.

4. Subjects who have completed end-of-treatment visits in the original study.

Exclusion Criteria:

1. Any unstable condition or condition that may compromise the safety of the subject.

2. Patients with new myelofibrosis were examined in the original clinical trial exit group.

3. The original clinical trial cohort examined evidence of new cataract or existing cataract progression, and the study considered it unsuitable to enroll in this extension.

4. Patients with uncontrolled bleeding after standard treatment.

5. Any previous occurrence of arterial or venous thrombosis (transient ischemic attack,myocardial infarction ,deep venous thrombus, or pulmonary embolism ),or clinical symptoms and history suggest thrombus susceptibility.

6. Any other circumstances that the investigator considers likely to cause the subject to be unable to complete the study or to present a significant risk to the subject.

Related Conditions & MeSH terms

• Immune Thrombocytopenia
• Purpura, Thrombocytopenic, Idiopathic
• Thrombocytopenia

Intervention

Drug:
• Herombopag
Thrombopoietin receptor agonist

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu HengRui Medicine Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of subjects with new myelofibrosis,new cataract, or existing cataract progression during the extended study.		from baseline to 28 days after the last dose
Primary	All AESIs,whether or not associated with study drugs.		from baseline to 28 days after the last dose
Primary	All SAEs,whether or not associated with study drugs.		from baseline to 28 days after the last dose
Primary	All AEs that result in discontinuation of medication.		from baseline to 28 days after the last dose
Primary	All AEs that lead to permanent withdrawal.		from baseline to 28 days after the last dose
Primary	Blood Biochemistry-ALT.		6 months
Primary	Blood Biochemistry-AST.		6 months
Primary	Blood Biochemistry-GGT.		6 months
Primary	Blood Biochemistry-ALP.		6 months
Primary	Blood Biochemistry-TBIL.		6 months
Primary	Blood Biochemistry-DBIL.		6 months
Primary	Blood Biochemistry-creatinine.		6 months
Secondary	Platelet count at each visiting point.		6 months
Secondary	The incidence and severity of bleeding symptoms.	According to the 2021 version go pediatric ITP bleeding Score Scale.	6 months
Secondary	Percentage of subjects receiving emergency treatment for aggravated ITP.		6 months
Secondary	Percentage of subjects with recurrent ITP.		6 months